Avacta Therapeutics (AIM:AVCT), the clinical-stage biopharmaceutical developing the pre|CISION tumour-activated delivery system, presented two new data sets at Science Day 2026 covering AVA6103 and AVA6207.
The AVA6103 analyses directly compared FAP-cleavable exatecan release from AVA6103 with released deruxtecan from Enhertu® and Datroway® in aligned cancer models.
"The data with our pre|CISION technology to deliver dual payloads has now demonstrated for the first time an efficacy advantage over single payload ADCs in a FAP-low and HER2-positive patient-derived cancer model," Christina Coughlin, Chief Executive Officer, said.
Avacta reported that released exatecan from AVA6103 reaches tumour Tmax in minutes versus more than 24 hours for Enhertu® or Datroway®.
The company said tumour Cmax of released payload from AVA6103 is over one log higher than the comparator ADCs.
Avacta also reported a tumour selectivity index (TSI = AUC[tumour/plasma]) at least three times higher for released exatecan from AVA6103 than for released deruxtecan from Enhertu® or Datroway®.
The company said it plans to publish the AVA6103 findings at an academic meeting and in a peer-reviewed journal.
In AVA6207 studies Avacta reported deep, durable complete responses in a FAP-high HEK-FAP model while conventional therapy showed tumour regrowth.
In a FAP-low, HER2-positive patient-derived gastric cancer model Avacta said AVA6207 produced durable responses where Enhertu®-treated tumours regrew, indicating the combination approach was more effective in that model.
The Science Day presentations were recorded and will be published on the company website.
